Translational Inflammation Summit
organised by
the International Association of Inflammation Societies (IAIS)
“Defining the Frontiers and Translational Pathways of Inflammation Research”

7-8 September 2012
Wapanak room (Conf centre)
Sagamore Resort, Bolton Landing, NY, USA

Organising Committee: Kouji Matsushima, John Hamilton,
Ian Ahnfelt-Rønne, Lisa Marshall

Breakfast will be served from 07.00–08.00 in the Triuna A+B (conf centre) on both days
All breaks take place in the Foyer Wapanak – conf centre
The venue for dinner on 7 September is: Morgan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Welcome and Introduction</td>
<td>Matsushima/ Hamilton</td>
</tr>
<tr>
<td></td>
<td>• Aim of the meeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Introduction of participants</td>
<td></td>
</tr>
<tr>
<td>08.20</td>
<td>Unmet Medical Need in Auto-Immune Diseases</td>
<td>Peen</td>
</tr>
<tr>
<td>08.45</td>
<td>Epigenetics and Rheumatoid Arthritis</td>
<td>Gay</td>
</tr>
<tr>
<td>09.10</td>
<td>Rheumatoid Arthritis: Towards Prevention of Disease?</td>
<td>Tak</td>
</tr>
<tr>
<td>09.35</td>
<td>Lessons learned from Biological Therapies</td>
<td>Strand</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>Regulatory Macrophages: Setting the Threshold for Therapy</td>
<td>Mosser</td>
</tr>
<tr>
<td>10.55</td>
<td>Extramedullary Hematopoiesis and Inflammation</td>
<td>Swirski</td>
</tr>
<tr>
<td>11.20</td>
<td>Inflammatory Signaling in Macrophages</td>
<td>Ivashkiv</td>
</tr>
<tr>
<td>11.45</td>
<td>Discussion of sessions 1 and 2</td>
<td>Gay/Gutierrez-Ramos</td>
</tr>
<tr>
<td>12.10</td>
<td>Lunch break</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Presenter</td>
</tr>
<tr>
<td>-------</td>
<td>------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>13.10</td>
<td>Contribution of IL-17 to the Chronicity of Inflammation</td>
<td>Miossec</td>
</tr>
<tr>
<td>13.35</td>
<td>Del-1, an Endogenous Anti-Inflammatory Regulator of IL-17 and Neutrophil Recruitment</td>
<td>Hajishengallis</td>
</tr>
<tr>
<td>14.00</td>
<td>Leukocyte Dynamics and Inflammation</td>
<td>Ley</td>
</tr>
<tr>
<td>14.25</td>
<td>Roles of Cytokines in Severe Asthma</td>
<td>Bing Yao</td>
</tr>
<tr>
<td>14.50</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td><strong>Session 4: Mechanisms in Inflammation III (Chairs: Miossec &amp; Ahnfelt-Rønne)</strong></td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td>The Resolution of Inflammation and Infection</td>
<td>Serhan</td>
</tr>
<tr>
<td>15.55</td>
<td>Covalent Inhibition Facilitates Translational Medicine: Bench to Bedside with Btk</td>
<td>Westlin</td>
</tr>
<tr>
<td>16.20</td>
<td><strong>Discussion of sessions 3 and 4</strong></td>
<td>Miossec/Ahnfelt-Rønne</td>
</tr>
<tr>
<td>16.40 - 17.00</td>
<td>End of day Summary and the Relation of New Science to the Unmet Medical Need</td>
<td>Peen/Miossec</td>
</tr>
<tr>
<td>19.00</td>
<td><strong>Dinner</strong></td>
<td></td>
</tr>
</tbody>
</table>
8 September

08.00  Discussion session: Inflammation Research in the Future  Hamilton/Peen

Session 5: Inflammation & Pathology II (Chairs: Matsushima & Iwakura)

08.30  The Role of GM-CSF in Alveolar Haemostasis, Lung Inflammation and Host Defence  Trapnell

08.55  Psoriasis: The Path of Translational Medicine  Krueger

09.20  Innovation in Large and Small Companies; Opportunities and Challenges  Esekowitz

09.55  Approaches to Blockade of Th2 Inflammation: Recent Advances  Graham

10.20  Coffee break

Session 6: Mechanisms in Inflammation IV (Chairs: Marshall & Faist)

10.50  Macrophage Differentiation  Geissmann

11.15  Inflammation and Metabolic Disease  Chawla

11.40  The Role of CTRP6 in the Development of Arthritis  Iwakura

12.05  Discussion of sessions 5 and 6  Marshall/Faist

12.30  Lunch break

Session 7: Inflammation & Pathology III (Chairs: Viney & Miossec)

13.30  Multiple Sclerosis  Owens

13.55  Chronic Pain  McMahon

14.20  Osteoarthritis and Inflammation  Abramson

14.55  Coffee break

Session 8: Inflammation & Pathology IV (Chairs: Viney & Miossec)

15.25  MadCam in IBD  Gutierrez-Ramos

15.50  Discussion of sessions 7 and 8  Viney/Miossec

16.15 - 17.00  Conclusion of summit and the way forward  Hamilton/Matsushima
PARTICIPANT INFORMATION

Steven B. Abramson, New York, NY, USA

Email: StevenB.Abramson@nyumc.org

Current position & affiliation
Professor of Medicine and Pathology, Senior Vice President and Vice Dean for Education, Faculty and Academic Affairs, Director of the Division of Rheumatology, NYU-Hospital for Joint Diseases, NYU Langone Medical Center and School of Medicine, New York, NY, USA

Former affiliations
- Dartmouth College, Hanover, USA and Harvard Medical School, Boston (MD)
- University Medical Center-Bellevue Hospital, New York (Chief Resident in Medicine/Chief Fellow in the Division of Rheumatology)

Main area of interest
- Arthritis, inflammation and drug treatments, with a recent focus on the role of inflammatory mediators produced by cartilage and synovial tissues.
- "Dr. Abramson's laboratory was among five designated by the NIH to be part of the Osteoarthritis Biomarkers Network, on which Dr. Abramson served on the Steering Committee. Under current NIH funding, Dr. Abramson's laboratory is exploring the role of inflammatory plasma and transcriptome biomarkers as predictors of OA incidence and progression."
- Dr. Abramson is co-director of the recently designated NYU Musculoskeletal Center of Excellence.

Ian Ahnfelt-Rønne, Maaløv, Denmark

Email: iar@novonordisk.com

Current position & affiliation
Corporate Vice President & Head of Pharmacology, Biopharmaceuticals Research, Novo Nordisk A/S, Denmark
Inflammation Research (Co-editor)
Basic & Clinical Pharmacology & Toxicology (Chairman of the Board)

Former affiliations
- Director of Pharmacology, LEO Pharma, Denmark
- President of the International Association of Inflammation Societies, IAIS
- Secretary of the European Inflammation Society, EIS

Main area of interest
- Pharmacology, inflammation research, endocrinology, haematology, drug discovery
**Ajay Chawla, San Francisco, CA, USA**

Email: Ajay.Chawla@ucsf.edu

**Current position & affiliation**
Associate Professor of Physiology and Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA, USA

**Former affiliations**
- University of Pennsylvania, Philadelphia (MD)
- Stanford University, Stanford (Assistant Professor of Medicine)
- Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, San Diego, CA (Postdoctoral Research Associate)
- UCSD Medical Center, San Diego, CA (Endocrinology Fellowship)

**Main area of interest**
- Transcriptional control of innate immune activation
- Role of innate immune cells in nutrient metabolism
- Immune determinants of tissue regeneration

---

**Alan Esekowitz, San Diego, CA, USA**

Email: alan@abidetx.com

**Current position & affiliation**
President and CEO, Abide Therapeutics

**Former affiliations**
- Merck Research Laboratories (Senior Vice President and Franchise Head, Bone, Respiratory, Immunology, Endocrine, Dermatology and Urology)
- Massachusetts General Hospital for Children and the Partners Healthcare System (chief of Pediatric Services)
- Harvard Medical School (Charles Wilder Professor of Pediatrics)

**Main area of interest**
- He is a pioneer in the field of innate immunity and has over 150 publications
- His work has focused on the fundamental problem of how the host defends itself in the first minutes and hours after exposure to an infectious challenge. His early work addressed the role of macrophage surface receptors and serum opsonin like the mannose-binding lectin in recognition of infectious agents.
- Later he turned to *Drosophila* as model system to study recognition and phagocytosis. He group postulated and demonstrated that primordial phagocytic receptors that recognize both apoptotic cells and microorganisms exist in fly phagocytes. His group was the first to show that fly phagocytes had properties that were similar to their mammalian counterparts and therefore constituted a valid and relevant model system to study phagocytosis. They used a systems biology approach to define the ~450 components of the *Drosophila* macrophage phagosome.
Eugen Faist, Munich, Germany

Email: Eugen.Faist@med.uni-muenchen.de

Current position & affiliation
Director Acute Care Surgery, Director Clinical Study Center, Director Laboratory “Acute Inflammation and Sepsis”, Department of Surgery, School of Medicine, LMU Munich, Klinikum Grosshadern, Germany

Former affiliations
- Yale University, School of Medicine, Dept. of Surgery (Clinical and research fellowship)

Main area of interest
- Trauma induced modifications of immune responses - individual cell analysis of T-lymphocyte, B-lymphocyte-and monocyte-behaviour. Major focus: Analysis of cytokine patterns under traumatic stress. Molecular biology analysis of the regulatory levels of pro-and anti-inflammatory cytokines in comparison to protein synthesis of corresponding mediators
- Characterization of positive and negative regulatory mechanisms of monocyte/T-cell interactions.
- Inflammatory properties of thrombolytic molecules (ATIII, APC)
- Clinical immunomodulatory studies in critically ill surgical patients
- Immunotherapy of sepsis
- Endotoxin determinations (EAA) under conditions of major trauma, liver transplantation and sepsis syndrome
- Interactions of pro-and anti-inflammatory cytokines of TH1 and TH2 type in surgical patients
- DAMPs and PAMPs molecules as biomarkers in trauma and sepsis
- Immunomonitoring in Critical Care

Per Falk, Måløv, Denmark

Email: pfal@novonordisk.com

Current position & affiliation
Senior Vice President of the Biopharmaceuticals Research Unit of Novo Nordisk A/S in Denmark

Former affiliations
- Associate Professor at the Karolinska Institute and Adjunct Associate Professor at the Washington University School of Medicine in St. Louis: Biochemistry, molecular biology and experimental gastroenterology
- Director Astra Zeneca: Cardivascular/Gastrointestinal Discovery
- Vice President Novo Nordisk A/S: Clinical Operations, Medical and Regulatory Affairs

Main area of interest
- Biopharmaceutical Drug Discovery
Steffen Gay, Zurich, Switzerland

Email: Steffen.Gay@usz.ch

**Current position & affiliation**
Professor of Experimental Rheumatology and Consultant Physician, Center for Experimental Rheumatology, Clinic of Rheumatology, University Hospital, Zurich, Switzerland

**Former affiliations**
- Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, USA (Professor of Medicine)

**Main area of interest**
- Epigenetics in the molecular and cellular basis of rheumatic disease
- Member of ‘Be The Cure’ (BTCURE), an IMI (Innovative Medicines Initiative) funded research project which aims to develop new therapies against rheumatoid arthritis. With a total budget of EUR 32 million and 33 partners from all over Europe, it is hoped that by combining academic and industrial resources, basic understanding of disease processes and therapeutic development will be enhanced.

Frederic Geissmann, London, United Kingdom

Email: cmcbi-admin@kcl.ac.uk

**Current position & affiliation**
Professor of Arthritis UK Chair of Inflammation Biology and Director of the Center for Molecular and Cellular Biology of Inflammation; King’s College London, London, UK

**Former affiliations**
- Hopital Necker, University Paris-Descartes, Paris, France (INSERM research Fellow)
- Department of Pathology, Hopital Necker, University Paris-Descartes (Assistant Professor)
- Skirball Institute, New York University, New York, USA (HFSPO Post-Doctoral fellow)
- Department of Cell Biology, Necker Hospital, University Paris-Descartes (Associate Professor)
- Department of Pathology, Necker Hospital, University Paris-Descartes (Consultant)
- Hopital Necker, University Paris-Descartes (Director INSERM unit 883 - Biology of the mononuclear Phagocyte System)

**Main area of interest**
- Development of myeloid cells, the cellular and molecular analysis of the functions of myeloid subsets, their roles in metabolism and inflammation, and the role of genetic heterogeneity in myeloid-expressed genes in human inflammatory diseases
Neil Graham, Tarrytown, NY, USA

Email: neil.graham@regeneron.com

Current position & affiliation
VP Program Direction, Immunology & Inflammation at Regeneron Pharmaceuticals

Former affiliations
• Vertex Pharmaceuticals
• Trimeris
• XTL Biopharmaceuticals
• MD, MPH, MBBS at University of Adelaide

Main area of interest
• Clinical Development,
• Drug Development
• Development Strategy

Jose-Carlos Gutierrez Ramos, Cambridge, MA, USA

Email: Jose-Carlos.Gutierrez-Ramos@pfizer.com

Current position & affiliation
Head of Biotherapeutics, Group SVP, Worldwide R&D, Pfizer, Inc

Former affiliations
• SVP and head of immuno-inflammation CEDD, GSK
• CSO Avidia/Amgen Mtn view
• CSO Peptimmune Inc
• VP head of inflammation Drug discovery, Millennium Pharmaceuticals

Main area of interest
• Cell migration
• Costimulation
• Innate receptors
• Epigenetics
• Drug discovery
Emma Guttman-Yassky, New York, NY, USA

Email: Emma.Guttman@mountsinai.org; eguttman@rockefeller.edu

Current position & affiliation
Assistant Professor of Dermatology and the Immunology Institute, Mt. Sinai Medical School, New York, NY, USA
Director of the contact dermatitis/occupational dermatitis
Director of the Laboratory for Inflammatory skin diseases
Visiting Assistant Professor, the Rockefeller University

Former affiliations
- Weill Cornell Medical College, Cornell University, New York, USA (MD)
- The Laboratory for Investigative Dermatology, the Rockefeller University, New York

Main area of interest
- Cellular and molecular pathogenesis of Inflammatory Skin diseases
- Atopic dermatitis (immune mechanisms and pathogenic pathway)
- Skin allergy and contact hypersensitivity
- Study of T cell, dendritic cell and keratinocyte activation responses using techniques including cell culture, flow cytometry, and genomic analyses

George Hajishengallis, Philadelphia, PA, USA

Email: geoh@upenn.edu

Current position & affiliation
Professor of Microbiology, Department of Microbiology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

Former affiliations
- University of Alabama, Birmingham, USA (Ph.D., postdoc)
- Louisiana State University Health Science Center, New Orleans, USA (Assistant Professor)
- University of Louisville, Louisville, USA (Associate Director of the Center for Oral Health and Systemic Disease, Professor at the School of Dentistry and School of Medicine)

Main area of interest
- Microbial pathogenesis, immunity, and inflammation
- Microbial immune evasion
- Impact of aging on inflammatory diseases
John A. Hamilton, Melbourne, Victoria, Australia

Email: jahami@unimelb.edu.au

Current position & affiliation
Deputy Head of Department, Dept of Medicine (RMH), The University of Melbourne
Professorial Fellow, University of Melbourne
Senior Principal Research Fellow, National Health and Medical Research Council of Australia
Director, Arthritis and Inflammation Research Centre, University of Melbourne

Former affiliations
• Founding Chief Executive Officer (part-time), Cooperative Research Centre for Chronic Inflammatory Diseases (2001-2004)

Main area of interest
• I am author of 301 publications (excluding abstracts) and my h-index is 55 (ISI Web of Knowledge). My major contributions have been towards the understanding of cytokine-mediated functions of macrophage lineage cells in inflammation/autoimmunity.
• The main focus of my current research is the control of the development of cells of the monocyte/macrophage lineage and the function of this lineage in inflammatory disease. More specifically it involves (i) animal models of inflammation, e.g. arthritis, with particular reference to the effects of CSF-1 and GM-CSF on disease progression, (ii) an analysis of the signal transduction pathways involved in the action of the CSFs, especially CSF-1(M-CSF), and (iii) characterization of monocyte/macrophage subpopulations. Several potential targets for drug intervention have arisen from this work. My work has specific relevance to arthritic disease, in particular, but also has wide implication for many aspects of inflammation and pathology, and therefore for many diseases.
Lionel Ivashkiv, New York, NY, USA

Email: IvashkivL@HSS.EDU

**Current position & affiliation**
Attending Physician (Rheumatology), Director of Basic Research and Associate Chief Scientific Officer, Hospital for Special Surgery, New York, NY, USA
Professor of Medicine and Immunology, Weill Cornell Medical College, Cornell University, New York, NY, USA

**Former affiliations**
- Harvard Medical School, Boston, USA (MD, Clinical Fellow, Instructor of Medicine)
- Hospital for Special Surgery, New York, USA (Director of the Arthritis and Tissue Degeneration Program)

**Main area of interest**
- Cytokine-mediated pathogenic mechanisms in autoimmune and inflammatory diseases
- Signal transduction crosstalk and downstream transcriptional regulation in cytokine signaling
- Jak-STAT signaling by cytokines and type I IFNs and dysregulation in rheumatoid arthritis and lupus
- Signaling to chromatin and epigenetic regulation of inflammatory macrophage phenotype

Yoichiro Iwakura, Tokyo, Japan

Email: iwakura@rs.tus.ac.jp

**Current position & affiliation**
Professor, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba 278-0022, Japan

**Former affiliations**
- Center for Experimental Medicine, Institute of Medical Science, University of Tokyo (Professor and Director)
- Laboratory Animal Research Center, Institute of Medical Science, University of Tokyo (Director and Professor)
- Department of Viral Infection, Institute of Medical Science, University of Tokyo (Associate Professor)
- Department of Cellular Virology, Institute for Virus Research, Kyoto University (Research Associate)

**Main area of interest**
- Pathogenic mechanisms of autoimmune arthritis
- Functional roles of cytokines, especially of IL-1 and IL-17
- Roles of C-type lectins in fungal infection and autoimmunity
James Krueger, New York, NY, USA

Email: kruegej@mail.rockefeller.edu

Current position & affiliation
Professor & Senior Physician, Laboratory Head, Investigative Dermatology, The Rockefeller University, New York, NY, USA

Former affiliations
- Weill Cornell Medical College, Cornell University, New York, USA (MD)
- The Rockefeller University, New York (assistant and associate Professor, head of lab, Codirector of the Center for Clinical and Translational Science)

Main area of interest
- Cellular and molecular pathogenesis of T cell-mediated autoimmunity
- Psoriasis vulgaris
- Cutaneous inflammation and autoimmune mechanisms in human skin
- Study of T cell, dendritic cell and keratinocyte activation responses using techniques including cell culture, flow cytometry and biochemical analysis

Klaus Ley, La Jolla, CA, USA

Email: klaus@liai.org

Current position & affiliation
Professor and Head, Division of Inflammation Biology, La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA

Former affiliations
- Freie Universität Berlin, Germany (Postdoctoral Fellow)
- University of California, San Diego, San Diego, USA (Postdoctoral Fellow)

Main area of interest
- Myeloid cells, specifically neutrophil and monocyte recruitment
- Research in atherosclerosis
Lisa Marshall, Collegeville, PA, USA

Email: lisa.marshall2@pfizer.com

Current position & affiliation
Senior Medical Director on the ENBREL team Pfizer Inc.

Former affiliations
- Johnson and Johnson (Leader Inflammation Drug Development)
- SmithKline Beecham (Director of Immunology Discovery)

Main area of interest
- Immune-mediated Inflammation

Others
- Oncology
- Tissue repair
- Osteoarthritis and Osteoporosis

Kouji Matsushima, Tokyo, Japan

E-Mail: koujim@m.u-tokyo.ac.jp

Current position & affiliation
Professor at the Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo

Former affiliations
- National Institute of Dental Research, Bethesda, MD, USA (Visiting Fellow)
- Lab. of Molecular Immunoregulation, Biological Response Modifiers Program, National Cancer Institute, Frederick, MD, USA
- Deptartment of Pharmacology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan (Professor)

Main area of interest
Chemokines, Cytokines, Macrophages:
Main goal of our research is providing novel ways and targets for preventing and treating intractable inflammatory and immune diseases through revealing their molecular and cellular mechanisms. Current interest of my laboratory is chronic inflammation-associated organ fibrosis, allo-HSCT associated chronic and acute GVHD, and the development of innovative methods to cure cancer and possibly AIDS through combining antibody and immuno-cell therapy.
Stephen McMahon, London, UK

Email: stephen.mcmahon@kcl.ac.uk

**Current position & affiliation**
Sherrington Professor of Physiology, King’s College London, UK
Director, London Pain Consortium, London, UK
Academic Lead, Europain (EU-IMI european pain consortium)

**Former affiliations**
- Head of Physiology, King’s College London
- Head of Neuroscience, King’s College London

**Main area of interest**
- Pain mechanisms
- Somatosensory systems
- Chemokine neurobiology
- Electrophysiology
- Human psychophysical studies

---

Pierre Miossec, Lyon, France

Email: pierre.miossec@univ-lyon1.fr

**Current position & affiliation**
Professor of Clinical Immunology, Hospital Edouard Herriot, Lyon, France

**Former affiliations**
- Brest University Hospital, Brest, France (MD)
- Department of Internal Medicine, Rheumatic Diseases Unit, University of Texas, USA (Research Fellow)
- Claude Bernard University Lyon, France (Professor of Clinical Immunology)

**Main area of interest**
- The role of cytokines and T cells in the context of arthritis
David M. Mosser, College Park, MD, USA

Email: dmosser@umd.edu

Current position & affiliation
Professor of Cell Biology and Molecular Genetics at the University of Maryland, College Park, MD, USA
Founding Director of the Maryland Pathogen Research Institute, University of Maryland, College Park, MD, USA

Former affiliations
- North Carolina State University, Raleigh, NC, USA (PhD)
- Harvard Medical School, Boston, MA (Postdoctoral Fellow)

Main area of interest
- Innate and adaptive Immunity to microbial pathogens
- How can leukocytes efficiently mediate host defense while minimizing autoimmune pathology

Trevor Owens, Odense, Denmark

Email: towens@health.sdu.dk

Current position & affiliation
Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Former affiliations
- University College London
- Walter and Eliza Hall Institute, Melbourne
- Montreal Neurological Institute, McGill University (Professor, coordinator Neuroimmunology Unit)

Main area of interest
- Neuroimmunology
Elisabeth Peen, Søborg, Denmark

Email: elpn@novonordisk.com

Current position & affiliation
MD DMSc Prof MPM
Head of Medical Affairs Inflammation, Novo Nordisk A/S in Denmark

Former affiliations
- University of Bergen, Norway
- University of Oslo, Norway
- University of Linköping, Sweden
- University of Florida, Gainesville, FL
- Genmab, Copenhagen, Denmark
- Roche HQ, Basel, Switzerland

Main area of interest
- Rheumatology and Autoimmune Diseases
- Clinical Immunology
- Internal Medicine

Charles N. Serhan, Harvard University, MA, USA

Email: cnserhan@zeus.bwh.harvard.edu

Current position & affiliations
Director, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital
The Simon Gelman Professor of Anaesthesia (Biochemistry & Molecular Pharmacology), Harvard Medical School
Professor of Oral Medicine, Infection & Immunity Harvard School of Dental Medicine

Former affiliations
- New York University School of Medicine
- Karolinska Institutet, Stockholm
- 2005-06 Chairman, Dept. of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine

Main area of interest
- Uncontrolled inflammation is now thought to play a key role in many diseases.
- I am devoted to the structural elucidation of bioactive mediators in inflammation and its resolution and to basic research in mechanisms that can impact human health and clinical care.
- In recent years, we focused on the isolation and structural elucidation of novel mediators and have identified a new genus of anti-inflammatory and pro-resolving mediators. My research group defined novel lipid mediators that stimulate and enhance resolution, i.e. pro-resolving mediators and stimulate organ regeneration.
- These provide a new directions to approach treatment of uncontrolled inflammation with agonists of essential pathways in host defense.
Vibeke Strand, Palo Alto, CA, USA

Email: vstrand@stanford.edu

Current position & affiliation
Clinical professor, Adjunct, in the Division of Immunology and Rheumatology, Stanford University School of Medicine
Leader of consulting practice offering clinical research and regulatory strategy expertise to pharmaceutical and biotech companies

Former affiliations
- Rheumatology subspecialty practice in San Francisco, CA, USA
- Clinical research investigator and senior director of clinical research at 3 pharmaceutical and biotech companies
- Associate Clinical Professor, Division of Rheumatology, University of California San Francisco School of Medicine

Main area of interest
- To help translate basic research into rational design of randomized controlled trials, evaluate their results, and defend approval of novel products to the FDA and EMA for autoimmune diseases, including rheumatoid arthritis [RA], osteoarthritis [OA], systemic lupus erythematosus [SLE], gout and fibromyalgia [FMS]
- Development of FDA Guidance Documents for products for treatment of rheumatic diseases including RA, OA, SLE, FMS, Chronic Pain
- Development and validation of outcome measures in rheumatic diseases as a member of the Executive Committee of OMERACT: Outcome Measures in Rheumatology international Consensus

Filip K. Swirski, Boston, MA, USA

Email: fswirski@mgh.harvard.edu

Current position & affiliation
Assistant Professor of Radiology, Harvard Medical School and Massachusetts General, Hospital, Boston, MA, USA

Former affiliations
- McMaster University, Hamilton, Canada
- Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

Main area of interest
- The role of leukocytes in innate immunity and cardiovascular disease
Paul-Peter Tak, Amsterdam, Netherlands

Email: P.P.Tak@amc.uva.nl

Current positions & affiliations
Senior Vice President, Head ImmunoInflammation Therapy Area Unit, GlaxoSmith Kline Pharmaceuticals Research & Development, Stevenage, U.K.; Professor of Medicine, Div. Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; Chief Scientific Officer, Arthrogen b.v., Amsterdam, the Netherlands

Former affiliations
- Leiden University Medical Center, Leiden, the Netherlands
- University of California San Diego, La Jolla, CA
- Dubai Bone & Joint Center, Dubai, UAE

Main area of interest
- Pathogenesis of different forms of arthritis
- Development and evaluation of targeted therapies for immune-mediated inflammatory disease

Bruce Trapnell, Cincinnati, OH, USA

Email: Bruce.Trapnell@cchmc.org

Current position & affiliation
F.R. Luther Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center and Research Foundation

Former affiliations
- University of Maryland, USA
- George Washington University, USA
- Ohio State University Hospitals, USA
- National Institutes of Health, USA (Senior Staff Attending Physician)
- Vice President, and Director of Virology and Pulmonary Studies, Genetic Therapy Inc./Novartis

Main area of interest
- Molecular pathogenesis, diagnosis, and therapy of rare lung disorders; the role of GM-CSF in lung structure and function; and human gene therapy
Jo Viney, Cambridge, MA, USA

Email: Jo.Viney@biogenidec.com

Current position & affiliation
Vice President, Immunology Research, Biogen Idec

Former affiliations
- Immunex/Amgen, Seattle/Thousand Oaks
- Genentech, South San Francisco (postdoctoral fellowship)
- Imperial Cancer Research Fund, London (postdoctoral fellowship)
- St Bartholomew's Hospital, University of London (PhD student)

Main area of interest
- Identification and validation of targets for drug discovery
- Developing novel small molecule and protein therapeutics for treating patients with chronic autoimmune, inflammatory and fibrotic disorders

William Westlin, Bedford, MA, USA

Email: wwestlin@celgene.com

Current position & affiliation
Vice President, Preclinical Research, Celgene Avilomics Research

Former affiliations
- VP, Preclinical Research, Avila Therapeutics, Bedford, MA
- Sr. VP, Preclinical Research, Praecis Pharmaceuticals, Waltham, MA
- Director, Pharmacia, St. Louis, MO
- Group Leader, Searle, St Louis, MO

Main area of interest
- Immuno-inflammatory diseases
- Role of B cells in autoimmune diseases
- Cell-cell communication at the blood vessel interface
- Drug discovery and development
- Pharmacology
Zhengbin (Bing) Yao, Gaithersburg, MD, USA

Email: Yaob@medimmune.com

Current position & affiliation
Sr. Vice President, Innovative Medicine for Respiratory, inflammation and Autoimmunity MedImmune

Former affiliations
- Genentech

Main area of interest
- Antibody drug development
- Cytokine and T cell biology

Other meeting participants

Andrew Glasebrook, Eli Lilly & Company, San Diego, CA, USA
Email: aglase@Lilly.com

Lily Liou, Kyowa Hakko Kirin California, Inc., La Jolla, CA, USA
Email: lliou@kyowa-kirin-ca.com

Arpita Maiti, Vertex Pharmaceuticals, Inc., Cambridge, MA, USA
Email: Arpita_Maiti@vrtx.com

Doug Morgan, Regeneron Pharmaceuticals, Tarrytown, NY, USA
Email: douglas.morgan@regeneron.com

Kevin Petty, Janssen R&D, Spring House, PA, USA
Email: kpetty@its.jnj.com

Robert Talanian, Abbott Bioresearch Center, Worcester, MA, USA
Email: bob.talanian@abbott.com

Staff participants

Sarah Cramton, Physicians World Europe

Trine Østergaard

Louise Scharff